spacer
home > pmps > winter 2002 > the scope of validation for cleanroom disinfectants
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Scope of Validation for Cleanroom Disinfectants

The validation of disinfectants for use in controlled environments can be both lengthy and expensive. This article examines the scope of disinfectant validation and how to ensure a smooth and successful outcome. As a disinfectant manufacturer we have a unique perspective on validation as not only do we have an in-depth knowledge of disinfectants but we also operate cleanrooms to the same cGMP standards as pharmaceutical manufacturers. It also allows us to gain a broad range of experience across the many life science fields including the pharmaceutical, biotechnology and medical device industries where similar issues arise repeatedly. The message is simple: consider all aspects of new agents right from the start. This will produce quick and meaningful validation results, which subsequently leads to early implementation of new disinfectants and prompt responses to audits.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Andrew Davidson, Commercial Director of Shield Medicare Ltd
Andrew Davidson is the Commercial Director of Shield Medicare Ltd. His qualifications include a BSc (Hons) in Biological Sciences and a CIM Diploma in Marketing. He has been with Shield Medicare for six years, having been recruited to develop the contamination control business. Before this he worked in the pharmaceutical industry for 15 years in both sales and marketing and product development roles.

spacer
Andrew Davidson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPI to showcase results from BioStreamline project developing novel biotherapeutics

CPI, a UK-based technology innovation centre and a founding member of the High Value Manufacturing Catapult, announced today that it will host an event in Darlington, UK on 26 June 2019 to disseminate the results of the 11.2M BioStreamline project to optimise the development of novel therapeutics. During the event, the project partners Lonza Biologics, UCB Celltech, Sphere Fluidics, Horizon Discovery Group plc (Horizon), Alcyomics Ltd and CPI will showcase the results and discuss the potential impact on overcoming some of the most significant shortcomings of the biologics supply chain.
More info >>

White Papers

The Key To Tableting Success: How To Choose The Right Tooling

Natoli Engineering Company, Inc.

Choosing the right tooling can increase tablet output, decrease waste and ultimately determine the success of a product launch.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement